TNFRSF8 and non-Hodgkin lymphoma: For NHL patients, the phase 3 ECHELON‐2 trial showed that the combination group (BV, cyclophosphamide, doxorubicin, and prednisone [A+CHP]) also achieved clinical benefit in terms of PFS (median PFS: 48.2 vs. 20.8 months; p = 0.0110) and OS (HR: 0.66; 95% CI: 0.46–0.95; p = 0.0244) compared with chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) for patients with treatment‐naive CD30‐positive PTCL,108 which led to an FDA approval.109, 110